tirzepatide by lilly Shows Superiority in SURMOUNT-3 and 4 The Weight Loss Drug That

Its important to inject the drug into a new site for each dose

Proper diagnosis ensures appropriate treatment

The mice in the intervention group received subcutaneous injections of tirzepatide (Eli Lilly and Company, Indianapolis, Indiana) with dose escalation: initially, 0.03 mg/kg for the first 4 weeks, followed by 0.1 mg/kg for the subsequent 4 weeks, culminating at 0.3 mg/kg for the final 4 weeks, with administrations twice weekly

Refrigerate immediately at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit)

In this study, we used ultra-performance liquid chromatography coupled with Orbitrap tandem mass spectrometry (UPLC-Orbitrap-MS/MS) for comprehensive metabolomics, lipidomics, and proteomics analyses with the aim of elucidating the potential molecular mechanisms through which tirzepatide alleviates MAFLD in mice fed a high-fat diet (HFD)